ǰÑÔ
ÂýÐÔ·ÎÔ´ÐÔÐÄÔಡ(chronic pulmonary heart disease, CPHD)ÊÇÓÉÂýÐÔÖ§Æø¹ÜÑס¢·ÎÆøÖס¢ÆäËûÐØ²¿¼²²¡¼°·ÎѪ¹Ü²¡±äÒýÆðµÄÐÄÔಡ£¬Ö÷Òª²¡Àí¸Ä±äΪ·ÎÑ»·¸ßѹ¡¢ÓÒÐÄÊÒÔö´ó¡¢ÓÒÐĹ¦Ð§²»È«¡£Ô¼Äª85£¥µÄCPHDÊÇÓÉÂýÐÔÛÕ±ÕÐԷμ²²¡(chronic obstructive pulmonary disease, COPD)ËùÒýÆðµÄ¡£Òò´Ë£¬¿ÉÒÔÒÔΪÂýÐÔ·ÎÔ´ÐÔÐÄÔಡÊÇÂýÐÔÛÕ±ÕÐԷμ²²¡µÄ×î³£¼û²¢·¢Ö¢¡£±¾½ÚÖ÷ÒªÏÈÈÝÓë·ÎÐIJ¡Ïà¹ØµÄ·ÎÑ»·¸ßѹ¶¯ÎïÄ£×ÓºÍÂýÐÔÛÕ±ÕÐԷμ²²¡Ä£×ӵĸ´ÖÆ¡£
ÂýÐÔÛÕ±ÕÐԷμ²²¡(chronic obstructive pulmonary disease, COPD)ÊÇÒ»ÖÖ¾ßÓÐÆøÁ÷ÊÜÏÞÌØÕ÷µÄÒÔÑ×֢Ϊ½¹µãµÄÂýÐÔºôÎüϵͳ¼²²¡£¬Óë·Î²¿¶ÔÏãÑÌÑÌÎíµÈÓк¦ÆøÌå»òÓк¦¿ÅÁ££¨ÌØÊâÊÇÎüÑÌ£©µÄÒì³£Ñ×Ö¢·´Ó¦Óйأ¬°üÀ¨¾ßÓÐÆøÁ÷ÛÕ±ÕÌØÕ÷µÄÂýÐÔÖ§Æø¹ÜÑ׺ͣ¨»ò£©·ÎÆøÖס£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÎüÑÌÊÇÈËÀàCOPD×îÖ÷ÒªµÄÖ²¡ÒòËØ£¬ÏãÑÌÖÐÓк¦ÒòËØ¿É¹¥»÷ÆøµÀÉÏÆ¤Ö±½ÓÏ÷ÈõºôÎüµÀµÄ¾»»¯ÄÜÁ¦ºÍ·ÀÓù¹¦Ð§£¬ÔöÌíÁ˷εÄ×ÜÎüÈë¿ÅÁ£ºÍÑÌÎíµÄ¼ç¸º£¬ÒýÆðÆøµÀÑ×Ö¢¼°¼Ì·¢µÄ·ÎÆøÖ׵ȣ¬Ò²¿É¼ÓÖØºôÎüµÀÖ¢×´ºÍÔö½øCOPDµÄ±¬·¢¡£Òò´Ë£¬½ÓÄɱ»¶¯ÎüÑ̽¨ÉèµÄCOPD¶¯ÎïÄ£×Ó¶øÐγɵĸıäÊÇÏÖÔÚËùÓÐÄ£×ÓÖÐ×î¿¿½üÈËÀàCOPD¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
ÖÆ±¸Óлú²£Á§ÑÌѬÏä(20cm×25cm×30cm)£¬ÑÌѬÏäµÄÒ»²à϶ËÁôÓÐÒ»¸öÖ±¾¶Îª0.5cmµÄÍ¨Æø¿×£¬¶Ô²àÓë²»Ðâ¸ÖµÄȼÑÌÊÒÏàÁ¬£¨Í¨£©£¬È¼ÑÌÊÒ½øÆø¿×ÅþÁ¬Ð¡Ð͵çÉÈ£¬ÏãÑÌÑÌÎíÔÚµçÉÈ·çÁ¦µÄÍÆ¶¯Ï½øÈëÑÌѬÏ䣬ʹÑÌÎíÔÚÏäÄÚÔȳÆÂþÑÜ£¬Í¬Ê±Ê¹ÑÌÎíÏäÄÚÓÐ×ã¹»µÄÑõÆø¡£Ñ¬ÑÌ×é´óÊóÓÚÖðÈÕÉÏ¡¢ÏÂÖç¸÷±»¶¯ÎüÑÌ1´Î£¬Ã¿¸öÑÌѬÏäÖÃÈëѬÑÌ×é´óÊó3Ö»£¬Ã¿Ïäÿ´ÎµãȼÊÐÊÛÎÞ¹ýÂË×ìË«Ï²ÅÆÏãÑÌ£¨Ô¼º¬½¹ÓÍ25mg£¬ÑÌÆøÑ̼îÁ¿1.4mg)3Ö§£¬Ã¿´ÎÒ»Á¬ÎüÈËÐÂÏʵÄÏãÑÌÑÌÎí1Сʱ¡£
¡¾ÔìÄ£ÌØµã¡¿£º
ѬÑÌ×é´óÊ󯸹ܡ¢Ö§Æø¹Ü¼°·Î×éÖ¯ÓÐÂýÐÔÖ§Æø¹ÜÑס¢ÛÕ±ÕÐÔ·ÎÆøÖ×µÄÌØÕ÷ÐÔ²¡Àí¸Ä±ä£¬×ÜÌåÌåÏÖΪÏËëÉÏÆ¤²¿·Ö°þÍÑ£¬Ö§Æø¹ÜÉÏÆ¤ºÍ³ÉÏËάϸ°ûÔöÉú±äºñ£¬ð¤ÒºÏÙ¼°±×´Ï¸°ûÔöÉú£¬¹ÜÇ»ÄÚð¤ÒºÈº¼¯£¬ÆøµÀ±ÚºÍСѪ¹ÜÖÜΧ·ÎÅÝÇøÒÔ¾ÞÊÉϸ°ûºÍÁܰÍϸ°ûΪÖ÷µÄÑ×ϸ°û½þÈó¡£ÑÌѬ10ÖܺóÏËëÉÏÆ¤Òì³£²¢Åãͬð¤Òº¸ßÉøÍ¸£»ÑÌѬ12Öܺó¿É¼ûÆøµÀÏËëÉÏÆ¤²¿·Ö°þÍÑ£»ÑÌѬ12~24Öܺó¿É¼ûһЩ·ÎÅÝÈÚºÏÐγɷδó°Ì£¬ÑÌѬ24~36ÖܺóÉÏÊö²¡Àí¸Ä±ä»»¼ÓÏÔ×Å£¬ÓÈÆäÔÚÑÌѬ36Öܺó·ÎÅÝÇ»ÏÔ×ÅÀ©´ó£¬ÆøµÀ¹Ü±ÚÏÔ×ÅÔöºñºÍÏËά»¯£¬²¢¿É¼û´ó×ÚÑ×ϸ°û½þÈó¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
½ÓÄÉѬÏãÑÌ36ÖܵÄÒªÁìÖÆ±¸´óÊóCOPDÄ£×Ó£¬Ëù½¨´óÊóCOPDÄ£×ÓÇкÏÈËÀàCOPDµÄÌØµã¡£¶àÖÖÑ×֢ϸ°û¼ÓÈëÁËCOPD±¬·¢¼°Éú³¤£¬ÆøµÀÇ»ÄÚÑ×֢ϸ°ûÒÔÖÐÐÔÁ£Ï¸°û¡¢¾ÞÊÉϸ°û¡¢ÁܰÍϸ°ûΪÖ÷£¬·ÎʵÖÊÒÔ¾ÞÊÉϸ°û(CD68+£©TÁܰÍϸ°ûÓÈÆäÊÇCD3+¡¢CD8+ϸ°û½þÈóΪÖ÷¡£IL-2¡¢IL-4¡¢IL-6¡¢IL-10¡¢IL-13¡¢IL-18¡¢IFN-γ¡¢µ¥ºËϸ°ûÇ÷»¯ÂѰ×(MCP-1£©ÄÚÆ¤ËØ(ET)-1ÔÚCOPDÆøµÀÑ×Ö¢ÖÐÆðÖ÷Òª×÷Óá£ÆøµÀð¤Òº¸ßÉøÍ¸¡¢Ñ×֢ϸ°ûÔö¶à¡¢ÆøµÀ±ÚÔöºñÇÒÒÔ½ºÔΪÖ÷µÄϸ°ûÍâ»ùÖÊÌ«¹ý³Á»ýÊÇCOPDÆøµÀÖØËܵÄÖ÷Òª²¡Àí¸Ä±ä£¬ÊÇÒýÆðÛÕ±ÕÐÔÍ¨Æø¹¦Ð§ÕϰµÄÖ÷ÒªÔµ¹ÊÔÓÉ¡£½ÓÄÉÆøµÀ×èÁ¦Óë·Î˳ӦÐÔ-RCϵͳ(BUXCO)¼ì²â´óÊóµÄÆøµÀ×èÁ¦ºÍ·Î˳ӦÐÔ£¬¸ÃÄ£×ÓÖ÷ÒªÓÃÓÚCOPD²¡Àí¡¢²¡ÀíÐÄÀí¸Ä±ä¼°ÆäÒ©ÎïÖÎÁƵÄÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.·½¸£µÂ£¬ÖÜÂÀ£¬¶¡å¥£¬µÈ. ÏÖ´úҽѧʵÑé¼¼ÇÉÈ«Ê飨ϲᣩ£®±±¾©£º±±¾©Ò½¿Æ´óѧÖйúкÍÒ½¿Æ´óѧÍŽá³öÊéÉ磬1995
2.ФʫÁÁ£¬¸ß˼º££¬Ñî³½Ô«£®³£Ñ¹È±ÑõÐÔ´óÊó·Î¶¯Âö¸ßѹģ×ÓµÄˢУ®ÁÙ´²ÐÄѪ¹Ü²¡ÔÓÖ¾£¬2001,17 (4):190
3.¾£Ö¾³É£®ÎÒ¹ú·Î¶¯Âö¸ßѹר¼Ò¹²Ê¶²ûÊÍ£®ÖйúÊÊÓÃÄÚ¿ÆÔÓÖ¾£¬2007,27 (4):246-249
4.ÕÔ誣¬ÁõÈØ£¬ÀîºéÌΣ¬µÈ£®Ò°°ÙºÏ¼îÓÕµ¼·Î¶¯Âö¸ßѹСÐÍÖíµÄ²¡Àí¸Ä±ä£®ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2012,32 (6):867-869
5.Allen K, Haworth SG. Impaired adaptation of pulmonary circulation to extrauterine life in newborn pigs exposed tohypox:ia:An ultrastructural study. J Pathol, 1986, 150(3): 205-212
6.Rahman I, Adcock lM. Oxidative stress and redox regulation of lung inilammal:ion in COPD. Eur Respi.r J, 2006, 28 (1):219-242
7.Sethi S,Mahler DA,Marcus P,el al. Inflammation in COPD:implications for management. Am J Med,2012, 125(12): 1162-1170
8.Tamimi A, Serrlarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD:Therapeulic implications. Respir Med,2012,106 (3):319-328